Mentions
Extended reach
Total likes
Video views
AI synopsis
Overall, these discussions reflect a cautious interest in the new findings, with some posts emphasizing the safety benefits of cryotherapy, like low morbidity, while others focus on its limited effectiveness, such as the 35% persistence of cancer. The tone varies from supportive to skeptical, which influences the neutral agreement and impact scores, highlighting a recognition of the research's importance but also its current limitations.
The discussions show mixed reactions; some express positive views on the safety aspects, while others highlight limitations with cryotherapy's effectiveness, indicating a neutral position overall.
Participants recognize the importance of prostate cancer treatments and recent research, demonstrated by the mention of multiple research groups and detailed findings, but the overall curiosity is moderate.
Many posts reference specific studies, methods, and outcomes, suggesting engaged analysis, but the tone remains somewhat informational rather than deeply investigative.
The conversations acknowledge the scientific value of the research and its potential influence on treatment choices, though some posts emphasize limitations and need for further validation, tempering the perceived impact.
Yet another trial of focal thermoablation, cryo, proving substandard results - 35% still had csPCa (only 46% had no PCa, and that neither MRI nor PSA were good indicators. Why is there no biochemical analysis to explain it? @BehfarEdhaie https://t.co/RytoPVjlSK
Researchers from @RadiologyUCLA, @UclaUrology, @UCLA_Pathology, @dgsomucla, @UAlberta & @AvendaHealth investigated the use of partial gland ablation with #cryotherapy for treatment of intermediate-risk #ProstateCancer. Here's what they found ➡️ https://t.co/QyMse7bget
Recent findings in #CancerMed following a prospective, observational trial of outpatient partial gland ablation #cryotherapy for prostate cancer: https://t.co/QyMse7bget Researchers from @RadiologyUCLA, @UclaUrology, @UCLA_Pathology, @dgsomucla, @UAlberta & @AvendaHealth.
New in #CancerMed: "Cryotherapy for partial gland ablation of prostate cancer: Oncologic & safety outcomes" by @RadiologyUCLA's Dr. Ely Felker & colleagues from @UclaUrology, @UCLA_Pathology, @dgsomucla, @UAlberta & @AvendaHealth. https://t.co/QyMse7bget
@MichaelAhdootMD @aleczhu @SGereta @JudithStKr @DoctorMargolis @TennyZhang @nyphospital @WCMUrology Our 43% comprehensive biopsy + rate (after censoring) at 2 years is similar to the Aker and Lenny Marks @UclaUrology series. We excluded Gleason 3+3 from analysis. Upside is low morbidity. https://t.co/cka7KQtBsr https://t.co/eBuZzUYaE5
This study explored cryotherapy as a partial gland ablation technique for prostate cancer, focusing on its safety and effectiveness over 6 to 18 months. Results showed most patients had no clinically significant…
@MichaelAhdootMD @aleczhu @SGereta @JudithStKr @DoctorMargolis @TennyZhang @nyphospital @WCMUrology Our 43% comprehensive biopsy + rate (after censoring) at 2 years is similar to the Aker and Lenny Marks @UclaUrology series. We excluded Gleason 3+3 from analysis. Upside is low morbidity. https://t.co/cka7KQtBsr https://t.co/eBuZzUYaE5
Recent findings in #CancerMed following a prospective, observational trial of outpatient partial gland ablation #cryotherapy for prostate cancer: https://t.co/QyMse7bget Researchers from @RadiologyUCLA, @UclaUrology, @UCLA_Pathology, @dgsomucla, @UAlberta & @AvendaHealth.
RT @RadiologyUcla: Researchers from @RadiologyUCLA, @UclaUrology, @UCLA_Pathology, @dgsomucla, @UAlberta & @AvendaHealth investigated the u…
Researchers from @RadiologyUCLA, @UclaUrology, @UCLA_Pathology, @dgsomucla, @UAlberta & @AvendaHealth investigated the use of partial gland ablation with #cryotherapy for treatment of intermediate-risk #ProstateCancer. Here's what they found ➡️ https://t.co/QyMse7bget
New in #CancerMed: "Cryotherapy for partial gland ablation of prostate cancer: Oncologic & safety outcomes" by @RadiologyUCLA's Dr. Ely Felker & colleagues from @UclaUrology, @UCLA_Pathology, @dgsomucla, @UAlberta & @AvendaHealth. https://t.co/QyMse7bget
RT @TallAllen: Yet another trial of focal thermoablation, cryo, proving substandard results - 35% still had csPCa (only 46% had no PCa, and…
RT @TallAllen: Yet another trial of focal thermoablation, cryo, proving substandard results - 35% still had csPCa (only 46% had no PCa, and…
RT @TallAllen: Yet another trial of focal thermoablation, cryo, proving substandard results - 35% still had csPCa (only 46% had no PCa, and…
RT @TallAllen: Yet another trial of focal thermoablation, cryo, proving substandard results - 35% still had csPCa (only 46% had no PCa, and…
RT @TallAllen: Yet another trial of focal thermoablation, cryo, proving substandard results - 35% still had csPCa (only 46% had no PCa, and…
RT @TallAllen: Yet another trial of focal thermoablation, cryo, proving substandard results - 35% still had csPCa (only 46% had no PCa, and…
RT @TallAllen: Yet another trial of focal thermoablation, cryo, proving substandard results - 35% still had csPCa (only 46% had no PCa, and…
Yet another trial of focal thermoablation, cryo, proving substandard results - 35% still had csPCa (only 46% had no PCa, and that neither MRI nor PSA were good indicators. Why is there no biochemical analysis to explain it? @BehfarEdhaie https://t.co/RytoPVjlSK
... 10.1002/cam4.1256. Ruckenstein M, 2017, ANNU REV ANTHROPOL, V46, P261, DOI ... P5692, DOI 10.1109/TWC.2020.2995594. Shukla AK, 2021, IEEE SENS J, V21 ...
Ancient Egypt is my area of focus, but I've participated on digs in Belize excavating Maya sites. As a modern-day archaeologist & historian, I ...
AE
UR
AM
JH
DU
EB
YR
IP
DS
AP
SA